Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPV-001 Pilot in Advanced Prostate Cancer
NCT02234921Phase 1Completed
- Sponsor
- UbiVac
- Start
- Oct 2014
- Primary completion
- Aug 2018
- Modality
- Whole Cell Cancer Vaccines, Oncolytic Viruses, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DPV-001 in prostate adenocarcinoma, sponsored by UbiVac. Primary endpoint: Safety and Tolerability Assessment at 28 weeks. Started Oct 2014; status: completed.
02
Drugs
DPV-001
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT02234921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234921.